Project HOPE (High-tech Omics-based Patient Evaluation) has been progressing since its implementation in 2014 using whole-exome sequencing (WES) and gene expression profiling (GEP). With the aim of evaluating immune status in cancer patients, a gene panel consisting of 164 immune response-associated genes (56 antigen-presenting cell and T-cell-associated genes, 34 cytokine-and metabolism-associated genes, 47 TNF and TNF receptor superfamily genes, and 27 regulatory T-cell-associated genes) was established, and its expression and mutation status were investigated using 1,000 cancer patient-derived tumors. Regarding WES, sequencing and variant calling were performed using the Ion Proton system. The average number of single-nucleotide variants (SNVs) detected per sample was 183 ± 507, and the number of hypermutators with more than 500 total SNVs was 51 cases. Regarding GEP, seven immune response-associated genes (VTCN1, IL2RA, ULBP2, TREM1, MSR1, TNFSF9 and TNFRSF12A) were more than 2-fold overexpressed compared with normal tissues in more than 2 organs. Specifically, the positive rate of PD-L1 expression in all patients was 25.8%, and PD-L1 expression was significantly upregulated in hypermutators. The simultaneous analyses of WES and GEP based on immune response-associated genes are very intriguing tools to screen cancer patients suitable for immune checkpoint antibody therapy.
However, since the recent success of immune checkpoint antibodies, such as ipilimumab and nivolumab, reported in metastatic melanoma patients, many ongoing clinical trials have been underway to evaluate their efficacy in various solid cancers other than melanomas (2, 8, 26, 31, 33) . Specifically, a promising combination therapy of ipilimumab and nivolumab has demonstrated a very high response rate of up to 40% and long-term survival benefit in patients with advanced cancers, including non-small cell lung cancer (18, 25, 29) .
to 2015. The cancer patient list is shown in Table 1 . Table 2 . In total, 164 immune response-associated genes [56 antigen-presenting cell (APC) and T-cell-associated genes, 34 cytokine-and metabolism-associated genes, 47 tumor necrosis factor (TNF) and TNF receptor superfamily genes, and 27 regulatory T-cell-associated genes] were selected. Specifically, regarding the regulatory T-cellassociated genes, 27 genes with more than 10-fold upregulation in CD4 + FoxP3 hi activated regulatory T cells compared with CD4 + FoxP3 low resting regulatory T-cells were screened (Microarray analysis of FoxP3-expressing or non-expressing subsets of human CD4 + T-cells dataset, http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE15659) (14) .
Establishment of the immune response-associated gene panel. The content of the immune response-associated gene panel is shown in
Immune response-associated gene expression analysis in cancer tissues. Total RNA was extracted from approximately 10 mg of tissue samples using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. As assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies), total RNA with an RNA integrity number of 6 or higher was used for DNA microarray analysis. Gene expression analysis was performed using SurePrint G3 Human GE 8 × 60 K v2.0 arrays (Agilent Technologies) according to the manufacturer's instructions. Signal data analysis was performed using GeneSpring version 13.1.1 software (Agilent Technologies). The ratio of the expression intensity between tumor tissue and surrounding normal tissue was calculated from Despite these promising results, the response rate associated with single antibody treatment is approximately 20-40% while 60-70% of cancer patients belong to the non-responding group. Furthermore, it is still difficult to accurately predict the responders to antibody therapy based on the current preclinical studies (16, 30) . Therefore, it is important and informative for clinicians administrating immune checkpoint antibody therapy that the immunological status of cancer patients can be accurately assessed before treatment in terms of the identification of the immune response-associated marker signature. The novel approaches to investigating immunological biomarkers for cancer immunotherapy such as immune checkpoint antibodies using next-generation sequencing are now ongoing between patients with or without a response to the antibody therapy for programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) (10, 20, 24) . In the present study, we established an immune response-associated gene panel consisting of 164 genes and investigated tumor-specific immune response-associated gene expression from 1,000 cancer patient-derived tumors from the Project HOPE (High-tech Omics-based Patient Evaluation) study, in which the simultaneous analyses of whole-exome sequencing (WES) and gene expression profiling (GEP) are performed (28, 34) . Furthermore, with a focus on PD-L1 gene expression and hypermutated tumors, which are probable biomarkers for immune checkpoint antibody therapy, the association of these biomarkers with the immune response-associated gene panel was also investigated. The evaluation of the immunological status in the tumor tissues before cancer immunotherapy using next-generation sequencing in Project HOPE should offer a promising novel approach to support the better prediction of responders to immune checkpoint antibody treatment.
MATERIALS AND METHODS

Patient registration.
This clinical research project using comprehensive WES and GEP of various tumor tissues, called HOPE, was conducted in accordance with the "Ethical Guidelines for Human Genome and Genetic Analysis Research", revised in 2013. Informed consent was obtained from all patients participating in Project HOPE, and was approved by the Institutional Review Board of Shizuoka Cancer Center, Japan. Tumor tissues, along with surrounding normal tissues, were dissected from surgical specimens by trained pathologists. One thousand cancer patients were registered in Project HOPE from 2014 The 988 of 1,000 tumors were verified to have both gene expression data by GEP and mutation data by WES and their data were used for genetic analysis.
nonsynonymous, synonymous, and indels/frameshift mutations.
Statistical analysis. The overall survival analysis based on the REMBRANDT dataset (http://www.betastasis. com/glioma/rembrandt/kaplan-meier_survival_curve/) regarding target genes was examined by comparing differences in the median survival time via the Kaplan-Meier method. A comparative analysis of the survival times between the gene groups was then performed using the log rank test. Statistical analyses were performed using Student's t-test and the MannWhitney test. Values of P < 0.05 were considered to be statistically significant.
RESULTS
Immune response-associated gene expression in 1,000 patient-derived tumors
In total, 988 of 1,000 tumors were verified to have both gene expression data by GEP and mutation data by WES and their data were used for expression analysis. The expression data of 164 immune normalized values. The ratio of more than 2.0 was rated as positive for gene expression. The ratio shown in log scale was used for heat map analysis. To investigate the association of PD-L1 with the expression of other genes, the expression ratios of immune response-associated genes between the PD-L1-positive and -negative groups were compared.
Whole-exome sequencing (WES) analysis of cancer tissues using next-generation sequencing.
WES and variant calling were performed using the Ion Proton with AmpliSeq Exome kit and Ion Torrent server as reported previously (28) . Briefly, all variants called by the variant caller were available; however, the data presented in Shizuoka Cancer Center represent those variants considered to be of good quality, based on the filtering in which sequences were discarded with a quality < 30, frequency < 10%, or coverage < 20. The obtained sequence data were likely somatic after the 2nd filtering to remove germline variants (using data from dbSNP, the 1,000 Genomes Project). Single-nucleotide variants (SNVs) of the total exonic mutations for each sequenced tumor included T cell and NKR gene:  56  CD80, CD86, CD274 (PD-L1), PDCD1LG2 (PD-L2), ISOSLG, CD276, VTCN-1,  LGALS9, SIRPB1, TREM1, CLEC5A, SIGLEC14, CD68, CD204(MSR1),  HLA-DQA, HLA-DRA, HLA-DRB1, CD19, CD28, CTLA4, CD279, ICOS, BTLA, SLAMF1,  HAVCR1, HAVCR2, TIMD4, TREML2, LAG3, ), TNFSF8, TNFSF9, TNFSF10,  TNFSF11, TNFSF12, TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF18,  TNFRSF1A, TNFRSF1B, EDAR, TNFRSF3 (LTBR), TNFRSF4, TNFRSF5 (CD40),  TNFRSF6 (FAS), TNFRSF6B, TNFRSF7 (CD27), TNFRSF8, TNFRSF9,  TNARSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A,  TNFRSF11B, TNFRSF12A, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF16  (NGFR), TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF19L (RELT), TNFRSF21,  TNFRSF25, TNFRSF27 (EDA2R)   ・Regulatory T cell-associated gene:  27  SEMA3G, LGALS3, ENTPD1, CCR4, CCRL2, CCR6, CCL20, IL12RB2, CCR10,  ANXA2, IL17RB, ADAM12, TMEM45A, LRRC32, CXCR6, LOXL1, GREB1, HRH4,  CCR5, HLA-DRB1, BMPR1B, SFRP1, LAMA2, ITGB1, CPE, MKI67, CDCA3  total 164 of PD-L1 expression in all cancer tissues was 25.8%. More than 40% of tumors were positive for PD-L1 expression in tumors of the uterus/ovary (Gy) and head and neck (HN) (Fig. 3) . By contrast, the frequency of PD-L1 expression was low in liver (H), pancreas (P), brain (N) and lung (T) tumors.
The association of PD-L1 expression with other genes
From the PD-L1 gene expression data in Fig. 3 , PD-L1 positive group (264 cases) and PD-L1 negative group (720 cases) were discriminated. Comparing the expression of immune response-associated genes other than PD-L1 between the PD-L1-positive and negative-groups, differentially regulated genes were identified. Significantly upregulated genes in the PD-L1-positive group were CTLA4, IL2RA, IDO1, TDO2, TNFSF9, TNFRSF9, STAT1, CCL20, and ICOS. On the other hand, downregulated genes in PD-L1 positive group were B7H3 and B7H4 (Fig. 4) .
Association of PD-L1 expression with a high mutation burden
The hypermutated tumor was tentatively rated as the response-associated genes using 988 tumors from various organs are shown in Fig. 1 . Tumor-specific upregulated genes of more than 2-fold compared with the non-cancerous tissues were identified in each organ (Table 3) . Subsequently, seven commonly upregulated genes in more than 2 organs were finally identified: VTCN1, IL2RA, ULBP2, TREM1, MSR1, TNFSF9 and TNFRSF12A.
Association of 7 identified genes with clinical prognosis
The association of 7 genes with clinical prognosis was evaluated using the REMBRANDT dataset based on gene expression and clinical data from glioma patients. Expression of the three genes TREM1, TNFRSF12A and MSR1 was positively correlated with a poor prognosis. However, 4 other genes, including VTCN1, showed no co-rrelation (Fig. 2) .
PD-L1 gene expression in various tumor tissues
More than 4.0 of the ratio of the PD-L1 gene expression intensity between tumor tissue and normal tissue was rated as positive. The mean positive rate tumor with more than 500 total SNVs. The average number of SNVs detected per sample of all tumors (988 cases) was 183 (total SNVs) and 120 (non-synonymous SNVs). Meanwhile, the average number of SNVs per sample of hypermutated tumors (51 cases) was 1706 (total SNVs) and 1124 (non-synonymous SNVs) (Fig. 5A) . PD-L1 expression was significantly higher in hypermutated tumors than that in nonhypermutated tumors (Fig. 5B) .
DISCUSSION
Since the innovative application of next-generation sequencing in cancer clinics, substantial novel evidence has been accumulated in the area of cancerassociated multi-omics. Next-generation sequencing technology has enabled clinicians and researchers involved in cancer immunology to study the molecular events occurring in the tumor microenvironment and has highlighted unresolved areas in tumor immunology. Specifically, genomic analysis of the tumor-infiltrating T-cell receptor repertoire is under progress using next-generation sequencing, which has taken much time and effort to generate a brief method for analyzing TCR repertoire (3, 6, 22, 23, 27) . Additionally, after the development of the immune checkpoint antibody, the assessment of the immunological status, including PD-L1 expression and mutation burden before treatment to predict the efficacy of antibody therapy more accurately, becomes more important.
In the present study, we investigated the expression of immune response-associated genes using tumors from 1,000 cancer patients in Project HOPE.
The original immune response-associated gene panel including T cell and APC, cytokine and metabolism, TNF superfamily and regulatory T cell gene, was established, and such an approach has rarely been Fig. 2 Association of 7 upregulated genes in the immune response-associated gene panel with overall survival for all glioma patients. The correlation of each gene expression level to the overall survival time was analyzed using Kaplan-Meyer survival analysis based on the REMBRANDT database of the National Cancer Institute. Only 3 genes, TREM1, TNFRSF12A and MSR1, were co-rrelated with overall survival. P < 0.05, statistically significant. (11, 19) . Therefore, immuno-suppressive genes such as VTCN1, TREM1, MSR1 and TNFSF12A might be good targets for antibody-based immunotherapy targeting M2 macrophages in the tumor. Next, PD-L1 expression and a high mutation burden are supposed to be biomarkers for responders of anti-immune checkpoint antibody therapy (17, 24) .
In the current study, we investigated the association of PD-L1 gene expression with the expression of other genes. The following genes were upregulated in expression in the PD-L1-positive group compared with PD-L1-negative group: TNFSF9, TNFRSF9 performed to date. Finally, 7 commonly upregulated genes in various tumors were identified: VTCN1, IL2RA, ULBP2, TREM1, MSR1, TNFSF9 and TNFRSF12A. Two points should be stressed here: 1) both immuno-stimulation and immuno-suppressionassociated genes are mixed, and 2) most genes are involved in tumor-associated macrophages. Regarding the 7 genes, all except IL2RA are known to be expressed on the surface of macrophages, and VTCN1, TREM1 and TNFSF12A are involved in immunosuppressive effects by the production of interleukin (IL)-6, IL-10 and transforming growth factor (TGF)-β, leading to myeloid-derived suppressor cells (MDSCs) and regulatory T cell induction (1, 4, 5) (Fig. 6 ). By contrast, ULBP2 and TNFSF9 are considered to stimulate T-cells and NK cells (7, 32) . Macrophage precursor cells migrate into tumor sites and are differentiated by macrophage colonystimulating factor (M-CSF), TGF-β and vascular endothelial growth factor (VEGF) produced from tumor cells (15) . Macrophages can be differentiated to dif- and STAT1 for immuno-stimulation, and CTLA4, IL2RA, IDO1, TDO2 and CCL20 for immuno-suppression. Considering these results, PD-L1 is involved in dual aspects of immuno-suppression and immuno-stimulation dependent on the current condition. The well-known mechanism for immuno-stimulation is through IFN-γ productions by effector T cells such as tumor-infiltrating lymphocytes (TILs), which, in turn, upregulate PD-L1 expression on tumor cells (13) . Interestingly, there were also upregulated genes in the PD-L1-negative group compared with the PD-L1-positive group: B7H3 and B7H4. These results could be alternative targets of anti-immune checkpoint antibody other than nivolumab in the case of PD-L1-negative tumors. Finally, the association of PD-L1 expression with a high mutation burden was investigated. Hypermutated tumors with more than 500 SNVs showed obviously higher PD-L1 expression than tumors with low mutation. The specific co-rrelation of PD-L1 expression with high mutations has been reported, and PD-L1 expression may be one parameter responsible for good responses in the clinic to anti-immune checkpoint antibody therapy (12) . In the future, the immune-response gene profiling of hypermutated tumors should be performed to identify better biomarkers to predict good responders to antibody treatment.
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